Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

A quick history of the tech behind J&J, AstraZeneca’s COVID-19 vaccines

By Brian Buntz | April 16, 2021

Adenovirus

Transmission electron micrograph of two Adenovirus particles. [Image courtesy of Wikipedia]

Regulatory authorities in the U.S. and Europe have either paused or constrained the use of COVID-19 vaccines from AstraZeneca (LON:AZN) and Johnson & Johnson (NYSE:JNJ), causing some to wonder why the adenoviral-vector vaccines have been potentially linked to similar blood clotting events.

Researchers have observed blood clotting events associated with adenoviral vectors since the late-1990s in early experiments with the platform. But the safety of the platform has improved as genetic engineering has advanced.

The history of using viruses as vectors dates back to the mid-1970s when scientists Dr. J. Michael Bishop and Dr. Harold Varmus demonstrated that gamma-retroviruses could acquire cellular genes.

Researchers began creating adenoviral vectors in the 1980s, testing replication-defective Ad vectors at that time. Most focused on adenovirus type 5 (Ad5).

Scientists believed that Ad5 held a particular promise for gene therapy to correct rare genetic mutations. Researchers had almost 70 years of experience developing adenovirus-based vaccines, which are distinct from adenoviral vectors. The U.S. military, for instance, administered live Ad types 4 (Ad4) and 7 (Ad7) to recruits in the 1950s, according to an article in Cell.

An early severe safety event

But one of the first recipients of an Ad5-based gene therapy died after treatment in 1999. That recipient, Jesse Gelsinger, had suffered from a rare genetic liver disease. The adenoviral-vector treatment shows promise in some animal studies but caused severe adverse events in Gelsinger. “When Jesse got the vector, he suffered a chain reaction that the testing had not predicted — jaundice, a blood-clotting disorder, kidney failure, lung failure and brain death,” according to an article from The New York Times. The patient had received a dose of 38 trillion viruses.

Gene therapy

Researchers have explored adenovirus vectors for both gene therapy and vaccines. Image courtesy of Wikipedia

While the vector generally seemed to work well in animal studies, three monkeys receiving it died of a blood-clotting disorder accompanied by severe liver inflammation. The monkeys had received an exceptionally high dose of the adenovirus vector.

Further generations of adenoviral vectors

Following this period, scientists backed away from using high doses of adenoviral vectors for gene therapy. But next-generation vectors have improved safety and immunogenicity. The potential of adenovirus vectors for gene therapy brightened.

The research spurred several developers to explore the use of the adenoviral vector platform for vaccines for a range of viruses, including Ebola and HIV. Experiments on the use of an Ad5 vector for HIV found an increased risk of HIV acquisition among vaccinated men, according to an article in The Lancet.

The use of adenovirus vectors for Ebola was more promising, resulting, ultimately, in the E.U. granting marketing authorization to such a vaccine for that virus.

Still a new technology

Before the introduction of adenovirus-vectored vaccines from AstraZeneca, Johnson & Johnson and others, however, such vaccines had not found broad use.

“There is only one [adenoviral vaccine] that has been approved so far,” said Navin Jacob, a UBS analyst referring to the Ebola vaccine from Johnson & Johnson that has won approval in Europe in 2020.

The Ad26 vector of the Johnson & Johnson COVID-19 vaccine has also been used in investigational vaccines for HIV, Zika, filovirus, HPV, malaria and respiratory syncytial virus. “As of December 2020, Ad26-based vaccines have been used to vaccinate 193,831 participants in clinical studies and vaccination programs and have exhibited acceptable clinical safety,” concluded a review of the Johnson & Johnson COVID-19 vaccine from UT Southwestern researchers.

In the Phase 3 trials for the AstraZeneca and Johnson & Johnson vaccines, reports of serious adverse events transverse myelitis led to pauses in the clinical trials. Investigators later deemed those events to be unrelated to the vaccines.

Researchers also logged one case of cerebral venous sinus thrombosis with thrombocytopenia among approximately 50,000 vaccine recipients in a Phase 3 trial for its Ad26.COV2.S vaccine. The company could not find a causal link between the condition and the vaccine.

Investigators also noted a numerical imbalance of thromboembolic events between vaccine and placebo recipients. Investigators determined that there were insufficient data to establish a causal relationship between the vaccine and the events.

The risk from adenoviral vector vaccines remains small overall

The overall risk of blood-clotting events from adenoviral vector COVID-19 vaccines “remains relatively low versus the risk associated with COVID-19,” Jacob said. “We’re talking about extremely rare events.”

There have been at least 222 suspected cases of such blood clots among 34 million vaccine recipients in Europe. More than 30 have died. In the U.S., there have been six such cases out of 7 million vaccinated individuals, including one death.

Still, there is reason to suspect such blood clotting events could be linked to adenoviral-vector vaccines. “The mechanism is not clear, but the events do appear to be very similar to the immune-mediated safety side effect associated with heparin-induced thrombocytopenia plus thrombosis,” Jacob said.

The problem might be specific to these adenoviral vector vaccines, but it is also unclear whether the issue will also apply to other similar vaccines in development. “It is not clear until the mechanism by which this is happening is clarified. It’s very hard to say,” Jacob said.


Filed Under: Infectious Disease
Tagged With: adenoviral vectors, adenovirus vectors, AstraZeneca plc, clinical trials, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Janssen Pharmaceutical Cos., Johnson & Johnson, SARS-CoV-2, vaccine
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE